Coherence principles in dose-finding studies

Ying Kuen Cheung

Biometrika, 2005, vol. 92, issue 4, 863-873

Abstract: This paper studies the coherence conditions of dose-finding methods in the context of phase I clinical trials, where the objective is to estimate a targeted quantile of the unknown dose-toxicity curve. Most phase I methods are outcome-adaptive, and thus escalate or de-escalate doses for future patients based on the previous observations. An escalation for a new patient is said to be coherent only when the previous patient does not show sign of toxicity. Likewise, a de-escalation is coherent only when a toxic outcome has just been seen. The coherence conditions, motivated by ethical concerns in trial conduct, are satisfied by many statistical designs in the literature, but not by some commonly used modifications of the methods. This paper shows examples in which coherence is violated, and discusses how the coherence principles may be applied to calibrate a two-stage design and to deal with situations with delayed toxicity. Copyright 2005, Oxford University Press.

Date: 2005
References: Add references at CitEc
Citations: View citations in EconPapers (6)

Downloads: (external link)
http://hdl.handle.net/10.1093/biomet/92.4.863 (text/html)
Access to full text is restricted to subscribers.

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:oup:biomet:v:92:y:2005:i:4:p:863-873

Ordering information: This journal article can be ordered from
https://academic.oup.com/journals

Access Statistics for this article

Biometrika is currently edited by Paul Fearnhead

More articles in Biometrika from Biometrika Trust Oxford University Press, Great Clarendon Street, Oxford OX2 6DP, UK.
Bibliographic data for series maintained by Oxford University Press ().